Results 41 to 50 of about 40,241 (253)

Economic aspects of biosimilar competition in Hungary — The treatment of rheumatic disorders [PDF]

, 2017
Biologicals are the fastest growing segment of the global pharmaceutical market, reaching 199 billion USD sales per year with 9.8% 10-year compound annual growth rate (CAGR).
Zrubka, Zsombor
core   +1 more source

Switching between reference adalimumab and biosimilars in chronic immune‐mediated inflammatory diseases: A systematic literature review

British Journal of Clinical Pharmacology, 2021
Adalimumab is a biological therapy used to treat different chronic inflammatory diseases. At present, there is an increasing number of adalimumab biosimilars. To assume the acceptability of interchangeability between reference adalimumab and biosimilars,
J. M. Pego Reigosa, N. García Beloso, Irene Altabás González, M. Samartin Ucha, M. Gayoso Rey, María Luísa De Castro Parga, Á. Salgado Barreira, Amelia Cibeira Badia, María Guadalupe Piñeiro Corrales, Daniel González Vilas, J. M. Pego Reigosa, Noemí Martínez López de Castro   +11 more
semanticscholar   +1 more source

Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study [PDF]

, 2016
Background Since 2007 biosimilars of erythropoiesis-stimulating agents (ESAs) are available on the Italian market. Very limited post-marketing data exist on the comparative effectiveness of biosimilar and originator ESAs.
Alibrandi, A. (Angela), Bolcato, J. (Jenny), Caputi, A.P. (Achille), Chinellato, A. (Alessandro), Fontana, A. (Andrea), Genazzani, A.A. (Armando A.), Giorgianni, F. (Francesco), Ientile, V. (Valentina), Ingrasciotta, Y. (Ylenia), Marcianò, I. (Ilaria), Pirolo, R. (Roberta), Santoro, D. (Domenico), Trifirò, G. (Gianluca)   +12 more
core   +6 more sources

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis

Dermatologic Therapy, 2022
The real-life effectiveness of adalimumab biosimilars in patients with psoriasis has rarely been investigated. To investigate drug survival of adalimumab biosimilars in patients with chronic plaque psoriasis and factors associated with its ...
F. Bellinato, P. Gisondi, Elena Mason, Paolo Ricci, M. Maurelli, G. Girolomoni   +5 more
semanticscholar   +1 more source

Biosimilar infliximab introduction into the gastro-enterology care pathway in a large acute Irish teaching hospital: a story behind the evidence [PDF]

, 2018
Background and aim: Biosimilar medicines are not considered exact replicas of originator biological medicines. As a result, prescribers can be hesitant to introduce such medicines into the clinical setting until evidence surfaces confirming their safety ...
Byrne, Stephen, Carrol, Donal, Courtney, Garry, Mulcahy, Mark, O'Brien, Gary L., Walshe, Valerie   +5 more
core   +1 more source

An Overview of Biosimilars—Development, Quality, Regulatory Issues, and Management in Healthcare

Pharmaceuticals
Biological therapies have transformed high-burden treatments. As the patent and exclusivity period for biological medicines draws to a close, there is a possibility for the development and authorization of biosimilars.
Filipa Mascarenhas-Melo, Mariana Diaz, M. B. S. Gonçalves, P. Vieira, Victoria Bell, Sofia Viana, Sara Nunes, A. C. Paiva‐Santos, Francisco Veiga   +8 more
semanticscholar   +1 more source

Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland [PDF]

, 2017
Increasing numbers of biosimilar medicines are becoming available. The objective of this survey was to assess awareness of and attitudes to biosimilars amongst physicians (medical specialists and General Practitioners (GPs)) and community pharmacists in ...
Bermingham, Margaret, Griffin, Brendan T., Hallinan, Frank, Leonard, Maurice, Moore, Una, Morris, J. Michael, O'Callaghan, Joan   +6 more
core   +1 more source

Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars

Drug Design, Development and Therapy, 2022
After 18 years and the administration of billions of doses, there is little doubt about biosimilars’ safety and efficacy. Yet, only 14 molecules in the EU and 9 in the US are available as biosimilars, among the 200+ targets, due mainly to the high ...
Sarfaraz K Niazi
semanticscholar   +1 more source

“Biosimilar, so it looks alike, but what does it mean?” A qualitative study of Danish patients' perceptions of biosimilars

Basic & Clinical Pharmacology & Toxicology, 2022
Biosimilars are highly similar follow‐on products for biologics that can foster biologics competition. Questionnaire studies have attempted to gauge the patient perspective on biosimilars, but none have delved deeper into how patients view biologics and ...
Meera Varma, A. Almarsdóttir, L. Druedahl   +2 more
semanticscholar   +1 more source

Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective

Expert Opinion on Biological Therapy, 2022
Introduction For many of the 537 million adults living now with diabetes, the cost of insulin is becoming prohibitive as the insulin prices have tripled between 2002–2013.
S. Joshi, Shivani Mittra, P. Raj, V. Suvarna, S. Athalye   +4 more
semanticscholar   +1 more source